Pharma-backed TransCelerate makes progress on clinical trial efficiency
This article was originally published in Scrip
TransCelerate BioPharma has taken swift action on all five objectives outlined in 2012 when the group was established by 10 big pharma companies to quickly address issues that hamper clinical trial efficiency, and the group has adopted a list of five new priorities.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.